Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Thrombophilia and its treatment in pregnancy
Autore:
Eldor, A;
Indirizzi:
Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Inst Hematol, IL-69978 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-69978 ematol, IL-69978 Tel Aviv, Israel
Titolo Testata:
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
fascicolo: 1, volume: 12, anno: 2001,
pagine: 23 - 30
SICI:
0929-5305(200109)12:1<23:TAITIP>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
MOLECULAR-WEIGHT HEPARIN; PROTEIN-C RESISTANCE; FACTOR-V-LEIDEN; LOW-DOSE ASPIRIN; VENOUS THROMBOEMBOLISM; ANTIPHOSPHOLIPID SYNDROME; FETAL LOSS; HIGH-RISK; INHERITED THROMBOPHILIA; GROWTH RESTRICTION;
Keywords:
pregnancy; venous thromboembolism; thrombophilia; obstetric complications; low molecular weight heparin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
76
Recensione:
Indirizzi per estratti:
Indirizzo: Eldor, A Ichilov Hosp, Tel Aviv Sourasky Med Ctr, Inst Hematol, 6 Weizman St, IL-64239 Tel Aviv, Israel Ichilov Hosp 6 Weizman St Tel Aviv Israel IL-64239 Aviv, Israel
Citazione:
A. Eldor, "Thrombophilia and its treatment in pregnancy", J THROMB TH, 12(1), 2001, pp. 23-30

Abstract

Pulmonary embolism is the most common cause of maternal death during pregnancy and the puerperium in the industrialized world. The risk of venous thromboembolism (VTE) in pregnancy is 0.05%-1.8%, 6 times greater than in the non-pregnant state. The risk is increased in women over 35 years and those with obesity, previous VTE, operative delivery, or underlying thrombophilia. Women presenting with recurrent miscarriages, preeclampsia, intrauterine growth restriction, abruptio placentae, or stillbirth (all associated with microvascular thrombosis in placental blood vessels) have high incidence (65%) of thrombophilia. About 70% of the women who present with VTE during pregnancy are carriers of hereditary or acquired thrombophilia. Treatment of women with VTE during pregnancy, and especially those with thrombophilia, requires individualized dosing and duration of antithrombotic therapy and the formulation of thromboprophylactic strategies for future pregnancies. Warfarin is contraindicated during the first trimester due to fetotoxicity; unfractionated heparin (UFH) is associated with practical disadvantages and the risk of heparin-induced thrombocytopenia (HIT) and osteoporosis with long-term use. Low molecular weight heparins (LMWHs) are convenient to use, donot cross the placenta, carry a lower risk of HIT and osteoporosis, and are safe and effective. LMWHs are replacing UFH as the anticoagulant of choice during pregnancy and improve pregnancy outcome in women with a history ofobstetric complications and confirmed thrombophilia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 23:55:08